Non-typeable Haemophilus influenzae protein vaccine in adults with COPD: A phase 2 clinical trial.

[1]  James R. Brown,et al.  Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations , 2018, Thorax.

[2]  A. Cripps,et al.  Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. , 2017, The Cochrane database of systematic reviews.

[3]  S. Wootton,et al.  A prospective, observational cohort study of the seasonal dynamics of airway pathogens in the aetiology of exacerbations in COPD , 2017, Thorax.

[4]  I. Carletti,et al.  Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial. , 2016, Clinical immunology.

[5]  P. van Damme,et al.  Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults. , 2016, Vaccine.

[6]  C. McDonald,et al.  Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease , 2016, Internal medicine journal.

[7]  James R. Brown,et al.  Lung microbiome dynamics in COPD exacerbations , 2016, European Respiratory Journal.

[8]  F. Martinez,et al.  The Microbiome and the Respiratory Tract. , 2016, Annual review of physiology.

[9]  Huaying Wang,et al.  Quantitative analysis of pathogens in the lower respiratory tract of patients with chronic obstructive pulmonary disease , 2015, BMC Pulmonary Medicine.

[10]  T. Murphy.  Vaccines for Nontypeable Haemophilus influenzae: the Future Is Now , 2015, Clinical and Vaccine Immunology.

[11]  Pierre Vandepapelière,et al.  Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: randomised, controlled trials. , 2015, Vaccine.

[12]  B. Lambrecht,et al.  Enhancement of Adaptive Immunity by the Human Vaccine Adjuvant AS01 Depends on Activated Dendritic Cells , 2014, The Journal of Immunology.

[13]  H. Boushey,et al.  Airway Microbiome Dynamics in Exacerbations of Chronic Obstructive Pulmonary Disease , 2014, Journal of Clinical Microbiology.

[14]  J. Poolman,et al.  Randomized Controlled Study of the Safety and Immunogenicity of Pneumococcal Vaccine Formulations Containing PhtD and Detoxified Pneumolysin with Alum or Adjuvant System AS02V in Elderly Adults , 2014, Clinical and Vaccine Immunology.

[15]  D. Sin,et al.  Bacterial microbiome of lungs in COPD , 2014, International journal of chronic obstructive pulmonary disease.

[16]  V. Pérez-Brocal,et al.  Bronchial microbiome of severe COPD patients colonised by Pseudomonas aeruginosa , 2014, European Journal of Clinical Microbiology & Infectious Diseases.

[17]  D. Boutriau,et al.  Safety, Immunogenicity, and Antibody Persistence following an Investigational Streptococcus pneumoniae and Haemophilus influenzae Triple-Protein Vaccine in a Phase 1 Randomized Controlled Study in Healthy Adults , 2013, Clinical and Vaccine Immunology.

[18]  Lorne A. Babiuk,et al.  Mechanisms of Action of Adjuvants , 2013, Front. Immunol..

[19]  W. Robinson,et al.  Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines. , 2013, Vaccine.

[20]  J. Hurst,et al.  COPD exacerbations: causes, prevention, and treatment. , 2013, Immunology and allergy clinics of North America.

[21]  The Unique Structure of Haemophilus influenzae Protein E Reveals Multiple Binding Sites for Host Factors , 2012, Infection and Immunity.

[22]  J. Wedzicha,et al.  Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD , 2012, Thorax.

[23]  A. Blom,et al.  Haemophilus influenzae protein E recognizes the C‐terminal domain of vitronectin and modulates the membrane attack complex , 2011, Molecular microbiology.

[24]  I. Carletti,et al.  An Adjuvanted Polyprotein HIV-1 Vaccine Induces Polyfunctional Cross-Reactive CD4+ T Cell Responses in Seronegative Volunteers , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  G. Leroux-Roels,et al.  H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses , 2010, Journal of Clinical Immunology.

[26]  R. Prymula,et al.  10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix™ , 2009, Expert review of vaccines.

[27]  A. Blom,et al.  Nontypeable Haemophilus influenzae Protein E Binds Vitronectin and Is Important for Serum Resistance1 , 2009, The Journal of Immunology.

[28]  V. A. Stewart,et al.  Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. , 2009, The Journal of infectious diseases.

[29]  G. Leroux-Roels,et al.  Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. , 2008, Vaccine.

[30]  A. Forsgren,et al.  Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  R. Munson,et al.  The PilA protein of non‐typeable Haemophilus influenzae plays a role in biofilm formation, adherence to epithelial cells and colonization of the mammalian upper respiratory tract , 2007, Molecular microbiology.

[32]  B. Grant,et al.  New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. , 2002, The New England journal of medicine.

[33]  A. Forsgren,et al.  Developing a nontypeable Haemophilus influenzae (NTHi) vaccine. , 2000, Vaccine.

[34]  N. Anthonisen,et al.  Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. , 1987, Annals of internal medicine.

[35]  G. Beeson,et al.  in adults with , 2019 .